Supernus Pharmaceuticals Inc

NASDAQ:SUPN  
27.48
+0.37 (+1.36%)
Products

Supernus Announces Qelbree SNDA For Adult Indication Accepted For Review By FDA

Published: 09/02/2021 22:54 GMT
Supernus Pharmaceuticals Inc (SUPN) - Supernus Announces Qelbree™ Snda for Adult Indication Accepted for Review by FDA.
Supernus Pharmaceuticals Inc - Snda is Now Considered Filed, With a User Fee Goal Date (pdufa Date) of April 29, 2022 .